Glycaemic Variability and Hyperglycaemia as Prognostic Markers of Major Cardiovascular Events in Diabetic Patients Hospitalised in Cardiology Intensive Care Unit for Acute Heart Failure.
acute heart failure
diabetes
glycaemic variability
major adverse cardiovascular event
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
11 Mar 2022
11 Mar 2022
Historique:
received:
04
02
2022
revised:
05
03
2022
accepted:
09
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
(1) Background: Hyperglycaemia and hypoglycaemia are both emerging risk factors for cardiovascular disease. Nevertheless, the potential effect of glycaemic variability (GV) on mid-term major cardiovascular events (MACE) in diabetic patients presenting with acute heart failure (AHF) remains unclear. This study investigates the prognostic value of GV in diabetic patients presenting with acute heart failure (AHF). (2) Methods: this was an observational study including consecutive patients with diabetes and AHF between January 2015 and November 2016. GV was calculated using standard deviation of glycaemia values during initial hospitalisation in the intensive cardiac care unit. MACE, including recurrent AHF, new-onset myocardial infarction, ischaemic stroke and cardiac death, were recorded. The predictive effects of GV on patient outcomes were analysed with respect to baseline characteristics and cardiac status. (3) Results: In total, 392 patients with diabetes and AHF were enrolled. During follow-up (median (interquartile range) 29 (6−51) months), MACE occurred in 227 patients (57.9%). In total, 92 patients died of cardiac causes (23.5%), 107 were hospitalised for heart failure (27.3%), 19 had new-onset myocardial infarction (4.8%) and 9 (2.3%) had an ischaemic stroke. Multivariable logistic regression analysis showed that GV > 50 mg/dL (2.70 mmol/L), age > 75 years, reduced left ventricular ejection fraction (LVEF < 30%) and female gender were independent predictors of MACE: hazard ratios (HR) of 3.16 (2.25−4.43; p < 0.001), 1.54 (1.14−2.08; p = 0.005), 1.47 (1.06−2.07; p = 0.02) and 1.43 (1.05−1.94; p = 0.03), respectively. (4) Conclusions: among other well-known factors of HF, a GV cut-off value of >50 mg/dL was the strongest independent predictive factor for mid-term MACE in patients with diabetes and AHF.
Identifiants
pubmed: 35329874
pii: jcm11061549
doi: 10.3390/jcm11061549
pmc: PMC8951492
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA. 2004 Jun 9;291(22):2727-33
pubmed: 15187054
Eur J Heart Fail. 2013 Apr;15(4):465-76
pubmed: 23186936
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Eur Heart J. 2014 Feb;35(7):455-69
pubmed: 24164864
Diabetes Care. 2009 Jun;32(6):1119-31
pubmed: 19429873
J Am Coll Cardiol. 2003 Aug 20;42(4):736-42
pubmed: 12932612
Diabetes Res Clin Pract. 2014 Sep;105(3):273-84
pubmed: 25023992
Congest Heart Fail. 2012 Sep-Oct;18 Suppl 1:S9-S13
pubmed: 22891803
Diabetes Res Clin Pract. 2013 Nov;102(2):86-95
pubmed: 24128999
Am Heart J. 2005 Feb;149(2):209-16
pubmed: 15846257
J Clin Epidemiol. 1995 Dec;48(12):1503-10
pubmed: 8543964
Diabetologia. 2021 Jan;64(1):42-55
pubmed: 33064182
J Diabetes Sci Technol. 2010 Nov 01;4(6):1382-5
pubmed: 21129333
Circulation. 2018 Dec 4;138(23):2627-2637
pubmed: 30571256
Diabetes Metab Res Rev. 2011 Jan;27(1):85-93
pubmed: 21218512
Eur J Heart Fail. 2015 Jan;17(1):109-18
pubmed: 25431336
Circulation. 2015 Jul 28;132(4):302-61
pubmed: 25547519
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
Diabetes. 2013 May;62(5):1405-8
pubmed: 23613566
Diabetes Care. 2017 Feb;40(2):171-180
pubmed: 27899497
Diabetes. 2017 Sep;66(9):2472-2482
pubmed: 28634176
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Heart. 2021 Oct;107(20):1657-1663
pubmed: 33431424
Crit Care. 2014 Apr 30;18(2):R86
pubmed: 24886864
Heart Fail Rev. 2018 May;23(3):303-323
pubmed: 29516230
Int J Cardiol. 2014 Dec 15;177(2):693-5
pubmed: 25449485
Diabetes Metab. 2019 Oct;45(5):446-452
pubmed: 30763700
Eur J Heart Fail. 2019 Oct;21(10):1259-1266
pubmed: 31359563
J Diabetes Sci Technol. 2012 May 01;6(3):712-5
pubmed: 22768904
JAMA. 2006 Apr 12;295(14):1681-7
pubmed: 16609090
Circ J. 2015;79(5):1092-9
pubmed: 25739857
JAMA. 2006 Apr 12;295(14):1707-8
pubmed: 16609094
Rev Neurol (Paris). 2022 Feb 23;:
pubmed: 35219541
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Eur J Heart Fail. 2016 Jun;18(6):613-25
pubmed: 27324686
Diabetes Care. 2019 Apr;42(4):674-681
pubmed: 30728222
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
N Engl J Med. 2009 Mar 5;360(10):961-72
pubmed: 19228612
Eur Heart J. 2013 Oct;34(39):3035-87
pubmed: 23996285
BMJ Open Diabetes Res Care. 2021 Mar;9(1):
pubmed: 33762313
Diabetes Metab J. 2015 Aug;39(4):273-82
pubmed: 26301188
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
J Am Coll Cardiol. 2021 Jan 26;77(3):243-255
pubmed: 33197559
Intern Emerg Med. 2021 Nov;16(8):2121-2128
pubmed: 33818704